Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Jetstar to Charge for Overhead Cabin Bags From February 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Telegram Restored on Apple App Store After Temporary Removal 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
NEW YORK, March 27, 2018 -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2017 financial results on Tuesday, April 3, 2018. BeyondSpring’s management team will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, April 3, 2018, to discuss the financial results and provide an operational update.
The conference call may be accessed by dialing (866) 362-6591 (U.S.) or (706) 758-3199 (international) and referencing conference ID 3765248. A live webcast will be available on the Investors page of the Company's website at http://ir.beyondspringpharma.com. An archived replay of the webcast will be available for 30 days.
About BeyondSpring
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer (Study 103) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN) – (Studies 105 and 106). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Contact:
Investor Relations:
Laura Perry or Joe Rayne
Argot Partners
212.600.1902
[email protected]
